•
Jun 30, 2021
Erasca Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided business updates.
Key Takeaways
Erasca reported a net loss of $28.2 million for the quarter ended June 30, 2021. The company nominated ERAS-3490 as its development candidate and dosed the first patient in HERKULES-1 study. Erasca completed a $345 million initial public offering in July 2021.
Nominated ERAS-3490 as development candidate from KRAS G12C inhibitor program in June 2021.
Dosed first patient in HERKULES-1 study in May 2021.
Completed $345 million initial public offering in July 2021.
Cash, cash equivalents, and investments were $198.7 million as of June 30, 2021.
Erasca
Erasca
Forward Guidance
Erasca expects to dose the first patient in HERKULES-2 in the third quarter of 2021 and the first patient in HERKULES-3 in the second half of 2021.